Aspirin

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Aspirin

NSAID, and an irreversible platelet inhibitor. The antiplatelet effect lasts the life of the platelet, roughly a week, long after the drug itself has cleared.

Evidence category: Regulator / guideline. This describes the source category, not approval or certainty.

Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.

Aspirin was the first antiplatelet medicine and irreversibly blocks the cyclooxygenase enzyme, cutting production of thromboxane A2, which drives platelet clumping. A pharmacology review describes antiplatelet therapy reducing cardiovascular risk after heart attack, bypass surgery and in atrial fibrillation, with aspirin still a mainstay. Neither linked source is a regulator label or a new trial; both are general reference texts. Dose-related trade-offs are not covered here.

Benefits reported in the imported source

• Labelled for headache, muscle pain, toothache, menstrual pain, cold fever and minor arthritis pain.
• A pharmacology review describes aspirin as a mainstay of antiplatelet therapy after heart attack.

Risks and limits

• The cardiovascular material comes from general reference texts, not a label or a new trial.
• How effects change with the amount used is not covered by the sources here.

Source bottom line: Aspirin is a labelled pain and fever medicine and a long-standing antiplatelet drug, per reference texts.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Pharmacokinetic context

Historical half-life estimate: 3 hours. FDA label, salicylate; dose-dependent Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Bayer Genuine Aspirin — US label (DailyMed)
• Aspirin: Pharmacology and Clinical Applications (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)
• Antiplatelet Medications - StatPearls (availability check 2026-10-15: possible access barrier; not independently inspected; HTTP 200)
• DailyMed: aspirin